INFLA-CARE
Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies
| Coordinatore | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
Organization address
address: N PLASTIRA STR 100 contact info |
| Nazionalità Coordinatore | Greece [EL] |
| Sito del progetto | http://inflacare.imbb.forth.gr/ |
| Totale costo | 16˙211˙687 € |
| EC contributo | 11˙999˙889 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-IP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-01-01 - 2013-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
Organization address
address: N PLASTIRA STR 100 contact info |
EL (HERAKLION) | coordinator | 1˙535˙724.20 |
| 2 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 1˙002˙290.00 |
| 3 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 835˙000.00 |
| 4 |
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Organization address
address: Al. Fleming Street 34 contact info |
EL (VARI-ATHENS) | participant | 828˙000.00 |
| 5 |
UNIVERSITAET ZU KOELN
Organization address
address: ALBERTUS MAGNUS PLATZ contact info |
DE (KOELN) | participant | 755˙976.00 |
| 6 |
INSTITUT GUSTAVE ROUSSY
Organization address
address: Rue Camille Desmoulins 39 contact info |
FR (VILLEJUIF) | participant | 671˙000.00 |
| 7 |
WEIZMANN INSTITUTE OF SCIENCE
Organization address
address: HERZL STREET 234 contact info |
IL (REHOVOT) | participant | 573˙000.00 |
| 8 |
BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
IL (BEER SHEVA) | participant | 571˙000.00 |
| 9 |
UNIVERSITAT WIEN
Organization address
address: UNIVERSITATSRING 1 contact info |
AT (WIEN) | participant | 544˙738.00 |
| 10 |
INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Organization address
address: Dr Bohrgasse 3 contact info |
AT (VIENNA) | participant | 518˙000.00 |
| 11 |
ISTITUTO GIANNINA GASLINI
Organization address
address: VIA GEROLAMO GASLINI 5 contact info |
IT (GENOVA) | participant | 512˙000.00 |
| 12 |
FORSCHUNGSZENTRUM BORSTEL
Organization address
address: Parkallee 1-40 contact info |
DE (BORSTEL) | participant | 511˙700.00 |
| 13 |
THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
UK (BIRMINGHAM) | participant | 510˙737.00 |
| 14 |
UNIVERZITA PALACKEHO V OLOMOUCI
Organization address
address: KRIZKOVSKEHO 8 contact info |
CZ (OLOMOUC) | participant | 502˙098.00 |
| 15 |
"SVEUCILISTE U RIJECI, MEDICINSKI FAKULTET"
Organization address
address: "B. Branchetta, 20 20" contact info |
HR (RIJEKA) | participant | 482˙200.00 |
| 16 |
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Organization address
address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA contact info |
ES (BARCELONA) | participant | 401˙578.00 |
| 17 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 394˙955.00 |
| 18 |
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNASKAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
Organization address
address: ALEXANDER FLEMING STREET 34 contact info |
EL (VARI) | participant | 332˙400.00 |
| 19 |
ALMAC DIAGNOSTICS LIMITED
Organization address
address: SEAGOE INDUSTRIAL ESTATE 20 contact info |
UK (CRAIGAVON) | participant | 180˙000.00 |
| 20 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | participant | 131˙422.02 |
| 21 |
HELIOS BIOSCIENCES SARL
Organization address
address: Avenue du General Sarrail 8 contact info |
FR (CRETEIL CEDEX) | participant | 113˙898.77 |
| 22 |
UNIVERSITY OF BRISTOL
Organization address
address: TYNDALL AVENUE SENATE HOUSE contact info |
UK (BRISTOL) | participant | 92˙171.98 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cells in the initiation, progression and metastasis of malignancy. The objective of the collaborative integrated project INFLA-CARE is to structure a European collective of scientific and technological excellence in the field of ‘Inflammation & Cancer’ which will capitalise on the available expertise and develop effective anti-inflammatory strategies and novel agents for cancer prevention and treatment. The project will specifically seek to identify molecular and cellular targets for cancer therapy through the development and systematic study of state-of-the-art pre-clinical models of inflammation-driven cancer. By mobilising the outstanding research experience and technological capacities of the network participants, the program will accelerate the translation of knowledge obtained by basic research into new diagnostic and therapeutic strategies which will be used for the detection, prevention and improved management of several types of human cancer. INFLA-CARE will also ensure spreading of scientific excellence and dissemination of knowledge beyond the network, by encouraging innovation and transfer of knowledge and by raising public understanding of scientific and health issues. The impact of the program is therefore expected to be multi-dimensional, namely scientific, educational and innovation-related, enhancing European competitiveness and addressing major scientific issues and societal needs.'
Introduzione (Teaser)
Chronic inflammation can cause cancers in areas such as liver, lung or colon that result in death within 3 years of detection due to lack of effective treatment options. The EU has funded a project to elucidate the correlation between inflammation and cancer incidence.
Descrizione progetto (Article)
Around 15 % of all malignant cancers are caused from chronic inflammation. Examples of these include hepatocellular carcinoma (HCC) due to hepatitis B or hepatitis C virus, colorectal cancers from ulcerative colitis and lung cancer from chemical irritants. Studies have found that inflammation from chronic exposure to toxic agents, irritants or autoimmune reactions has been linked to malignant cancers with high fatality.
INFLA-CARE is a collaborative project funded by the EU to understand the molecular mechanisms behind inflammation-driven cancer. Project researchers used pre-clinical mouse models to understand tumour formation and progression at the cellular level on exposure to chronic inflammation.
They have successfully developed mouse models to mimic cancers resulting from inflammation and have thus been able to characterise the response of immune cells to cancer metastasis and therapy. The roles of cell-signalling molecules such as interleukin 1a (IL1a) and IL1b in colitis and colitis-associated colon cancer, deoxyribonucleic acid (DNA) damage response (DDR) and DDR-related molecular pathways were defined. The scientists are also assessing the involvement of signalling networks and lymphocytic populations in primary human tumours and cell lines in human cancer associated with chronic inflammation. Research outcomes will be used to curtail cellular pathways involved in inflammation-driven cancer and to bolster immune responses that prevent cancer formation or improve treatment response. Promising modalities could be optimised and tested for use in combination with conventional cancer treatment methods. Research findings to date have been disseminated through summer schools, seminars, conferences, lectures and publications.
Currently, treatment options for inflammation-driven cancers are limited and ineffective resulting in high mortality and morbidity. Findings from INFLA-CARE research may result in breakthroughs that will benefit such cancer patients and save lives.